Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
3 min read
Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.
Latest Hotspot
3 min read
The FDA gives IND approval for Biosyngen's BST02, the first global TIL treatment for liver cancer
2 November 2023
The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.
Drug Insights
4 min read
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
2 November 2023
This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.
Latest Hotspot
3 min read
Deciphera announces positive top line results from pivotal Phase 3 trial of vimseltinib in treatment of Tenosynovial Giant Cell Tumors
2 November 2023
Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).
Valuable Targets
7 min read
Analysis on the Clinical Research Progress of ERK Inhibitor
2 November 2023
ERK, also known as Extracellular Signal-Regulated Kinase, is a crucial protein kinase that plays a significant role in various cellular processes within the human body.
Latest Hotspot
3 min read
The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL
2 November 2023
Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.
Drug Insights
4 min read
Pharmaceutical Insights: Cocaine Hydrochloride's R&D Progress
2 November 2023
This article summarized the latest R&D progress of Cocaine Hydrochloride, the mechanism of action for Cocaine Hydrochloride, and the drug target R&D trends for Cocaine Hydrochloride.
Latest Hotspot
3 min read
The novel Aβ-targeting drug Donanemab by Eli Lilly is applying for market authorization in China to treat Alzheimer's disease
2 November 2023
Recently, the official website of the CDE shows that the marketing authorization application for Eli Lilly's new Alzheimer's medication, donanemab, has been accepted.
Valuable Targets
6 min read
Advances in Clinical Research on D2 Receptor Antagonist
2 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Latest Hotspot
3 min read
The positive data from Apellis' Phase 3 study on pegcetacoplan was published in The Lancet, targeting the main cause of blindness in the elderly
1 November 2023
Recently, Apellis Pharmaceuticals announced that The Lancet published positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan) .
Drug Insights
3 min read
Exploring Dactinomycin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
1 November 2023
This article summarized the latest R&D progress of Dactinomycin, the Mechanism of Action for Dactinomycin, and the drug target R&D trends for Dactinomycin.
Latest Hotspot
4 min read
The latest phase II clinical research by Innovent Biologics on Mazdutide, a GLP-1R/GCGR dual agonist, has been released, showing significant weight loss effects
1 November 2023
Innovent Biologics recently announced the completion of the 48-week treatment phase after reaching the primary endpoint of the phase II clinical trial in obese Chinese subjects with 9mg of the GLP-1R/GCGR dual agonist, Mazdutide.